CL2022002290A1 - Sodium acetate monohydrate, its preparation and use - Google Patents

Sodium acetate monohydrate, its preparation and use

Info

Publication number
CL2022002290A1
CL2022002290A1 CL2022002290A CL2022002290A CL2022002290A1 CL 2022002290 A1 CL2022002290 A1 CL 2022002290A1 CL 2022002290 A CL2022002290 A CL 2022002290A CL 2022002290 A CL2022002290 A CL 2022002290A CL 2022002290 A1 CL2022002290 A1 CL 2022002290A1
Authority
CL
Chile
Prior art keywords
preparation
acetate monohydrate
sodium acetate
dihydroquinazoline
cytomegalovirus
Prior art date
Application number
CL2022002290A
Other languages
Spanish (es)
Inventor
Buschmann Helmut
Goldner Thomas
Carles Ceron Bertran Jordi
Original Assignee
Aic246 Ag & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Ag & Co Kg filed Critical Aic246 Ag & Co Kg
Publication of CL2022002290A1 publication Critical patent/CL2022002290A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la nueva 3,4-dihidroquinazolina, 2- [(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4H-quinazolin-4-il] acetato de sodio monohidrato, métodos 10 para su preparación, así como composiciones farmacéuticas que contienen dicha 3,4-dihidroquinazolina. Dicho compuesto es particularmente útil para el tratamiento y prevención de enfermedades asociadas con citomegalovirus (CMV), particularmente citomegalovirus humano (HCMV).The present invention relates to the new 3,4-dihydroquinazoline, 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5 Sodium (trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate, methods for its preparation, as well as pharmaceutical compositions containing said 3,4-dihydroquinazoline. Said compound is particularly useful for the treatment and prevention of diseases associated with cytomegalovirus (CMV), particularly human cytomegalovirus (HCMV).

CL2022002290A 2020-02-27 2022-08-22 Sodium acetate monohydrate, its preparation and use CL2022002290A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20159709 2020-02-27

Publications (1)

Publication Number Publication Date
CL2022002290A1 true CL2022002290A1 (en) 2023-02-03

Family

ID=69742712

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002290A CL2022002290A1 (en) 2020-02-27 2022-08-22 Sodium acetate monohydrate, its preparation and use

Country Status (19)

Country Link
US (1) US20230219900A1 (en)
EP (1) EP4110469A1 (en)
JP (1) JP2023519809A (en)
KR (1) KR20220147655A (en)
CN (1) CN115427111A (en)
AR (1) AR121440A1 (en)
AU (1) AU2021225364A1 (en)
BR (1) BR112022016906A2 (en)
CA (1) CA3169473A1 (en)
CL (1) CL2022002290A1 (en)
CO (1) CO2022012017A2 (en)
CU (1) CU20220047A7 (en)
EC (1) ECSP22066670A (en)
IL (1) IL295633A (en)
MX (1) MX2022010440A (en)
PE (1) PE20230347A1 (en)
TW (1) TW202140454A (en)
UY (1) UY39098A (en)
WO (1) WO2021170879A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024037485A1 (en) * 2022-08-15 2024-02-22 上海迪赛诺化学制药有限公司 Preparation method for letermovir amorphous form

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (en) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituted dihydroquinazolines
DE102005027517A1 (en) 2005-06-15 2006-12-21 Bayer Healthcare Ag Process for the preparation of dihydroquinazolines
DE102012101659A1 (en) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salts of a dihydroquinazoline derivative

Also Published As

Publication number Publication date
CN115427111A (en) 2022-12-02
IL295633A (en) 2022-10-01
AU2021225364A1 (en) 2022-10-13
KR20220147655A (en) 2022-11-03
MX2022010440A (en) 2022-10-18
AR121440A1 (en) 2022-06-08
CU20220047A7 (en) 2023-04-10
JP2023519809A (en) 2023-05-15
UY39098A (en) 2021-09-30
TW202140454A (en) 2021-11-01
US20230219900A1 (en) 2023-07-13
CO2022012017A2 (en) 2022-11-18
WO2021170879A1 (en) 2021-09-02
PE20230347A1 (en) 2023-03-02
CA3169473A1 (en) 2021-09-02
EP4110469A1 (en) 2023-01-04
ECSP22066670A (en) 2022-12-30
BR112022016906A2 (en) 2022-12-06

Similar Documents

Publication Publication Date Title
BRPI0409227B8 (en) "compound, pharmaceutical composition, use of a compound and process for the preparation of a compound of formula (i)"
CY1111170T1 (en) UNIVERSAL BUSINESS ESSENTIAL URINE
BRPI0411255A (en) compound, pharmaceutical composition, use of a compound, methods of treating a disorder of a patient, and process for the preparation of a compound
PE20141540A1 (en) DERIVATIVES OF 2-AMINO-4- (PYRIDIN-2-IL) -5,6-DIHIDRO-4H-1,3-OXAZINE AND THEIR USE AS INHIBITORS OF BACE-1 AND / OR BACE-2
NO20062905L (en) Novel hydroxamic acid esters and their pharmaceutical use
ATE541572T1 (en) TETRAHYDRO-NAPHTALIN DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS
DE60321775D1 (en) CARBOXIC ACID DERIVATIVES CONTAIN A PIPERAZINE COMPOUND AS HDAC INHIBITORS
BRPI0409109A (en) new compounds
BRPI0519287A2 (en) amide derivatives
BRPI0720220B8 (en) quinoline derivative, its pharmaceutical composition, its use, its preparation process, combination and product comprising it
FR2903107B1 (en) IMIDAZOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
PE20140966A1 (en) QUINAZOLINE CARBOXAMIDE AZETHYDINES
BR112014006763A2 (en) n- (3- (2-amino-6,6-difluoro-4,4a, 5,6,7,7a-hexahydro-cyclopenta [e] [1,3] oxazin-4-yl) -phenyl) -amides as bace1 inhibitors
CL2022002290A1 (en) Sodium acetate monohydrate, its preparation and use
NZ607580A (en) N-heteroaryl compounds
PH12019500597A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
BRPI0607214B8 (en) hiv inhibitors 2-(4-cyanophenylamino)pyrimidine derivatives, pharmaceutical composition comprising them and their preparation processes
BRPI0719920B8 (en) quinoline derivative, its pharmaceutical composition, its use, its preparation process, combination and product comprising the same and intermediate compound
MX2021009971A (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof.
MX2014014066A (en) Chromane compounds.
EA201401238A1 (en) Fluoro-substituted (3R, 4R, 5S) -5-GUANIDINO-4-ACYLAMINO-3- (PENTAN-3-ILOXI) CYCLOHEXEN-1-CARBONIC ACIDS, THEIR ETHERS AND METHOD OF APPLICATION
AR061433A1 (en) AMIDA COMPOUNDS OF ACID 3-AMINO-TIENO (2,3, B) PIRIDINA -2-CARBOXILICO REPLACED, PROCESSES FOR THEIR PREPARATION AND USES OF THE SAME
PA8661101A1 (en) ANTIHELMINTIC COMPOUNDS
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
BRPI0719939B8 (en) quinoline derivative, its pharmaceutical composition, its use, its preparation process, combination and product comprising it